ReviewAesthetic surgery journal2017
New Uses of AbobotulinumtoxinA in Aesthetics.
Review in Aesthetic surgery journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Efficacy and safety of botulinum toxin-A injection in the treatment of premature ejaculation: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Network Meta-Analysis of Different Clinical Commonly Used Drugs for the Treatment of Hypertrophic Scar and Keloid.Frontiers in medicine · 2021Pooled it
- Trial
- Non-Surgical Ear Rejuvenation Through Selective Neuromodulation with Onabotulinum and Abobotulinum Toxin-A.Toxins · 2026Article
- Targeting Neurovascular Inflammation in Rosacea: A Systematic Review of Botulinum Toxin Therapy.Cureus · 2026Review
- Endothelial system dysregulation underlies keloid development and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
- Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.Journal of clinical medicine · 2025Review
- Botulinum Toxin in Aesthetic Medicine: A Bibliometric Analysis of Research Trends and Methodological Quality of the Top 100 Cited Publications.Aesthetic surgery journal. Open forum · 2025Article
- Personality Traits and Motivations of Chinese Adults Seeking Cosmetic Botulinum Toxin Injection.Clinical, cosmetic and investigational dermatology · 2025Article
- Prospects for Use of Botulinum Toxin Type A for Prevention of Hypertrophic and Keloid Scars after Surgeries.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2024Article
- Article
- Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.Toxins · 2024Review
- [Research advances on application of botulinum toxin type A in scar prevention and treatment].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2022Review
- Keloids: a review of therapeutic management.International journal of dermatology · 2021Review
- Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.The Journal of clinical and aesthetic dermatology · 2021Article
- Use of Botulinum Toxin in Treating Rosacea: A Systematic Review.Clinical, cosmetic and investigational dermatology · 2021Article
- Intradermal Micro-Dosing of AbobotulinumtoxinA for Face-Lifting: How Long Does It Last?Dermatology and therapy · 2020Article
- Botulin Toxin Use in Rosacea and Facial Flushing Treatment.Open access Macedonian journal of medical sciences · 2019Review
- Botulin Toxin Use in Scars/Keloids Treatment.Open access Macedonian journal of medical sciences · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BotulinumtoxinA (BoNT-A) is now widely established for the main approved indication of reducing glabellar lines, and is also widely used off-label to improve the appearance of wrinkles and lines in other parts of the face. The number of aesthetic procedures continues to increase as the patient population becomes more diverse, in particular with increasing numbers of people of color and men. Further developments in treatment may continue to expand the audience for BoNT-A by making procedures more comfortable and by delivering a more natural, less static appearance. These may be achieved through use of combinations of BoNT-A with other aesthetic procedures, tailoring the dose of toxin to the patient's muscle mass or by using novel injection and application techniques. Beyond amelioration of facial lines, encouraging results have been seen with the use of BoNT-A to improve the appearance of hypertrophic and keloid scars and even to prevent them. Studies have been conducted with scars in various parts of the body and further research is ongoing. Dermatological and other medical uses for BoNT-A are also active areas of research. Injections of BoNT-A have been shown to reduce signs and symptoms of acne, rosacea, and psoriasis, to reduce neuromuscular pain, and to bring about significant improvements in a number of rare diseases that are caused or exacerbated by hyperhidrosis. This paper reviews these new uses for BoNT-A, looking at the rationale for their use and discussing the results of published case studies and clinical trials. These areas have shown great promise to date, but more and larger clinical studies will be required before these treatments become a clinical reality. To this end details are also provided of clinical trials currently listed in the main clinical trials database to highlight research areas of particular interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.